Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cambodia surveillance study of artesunate-mefloquine and artesunate-pyronaridine for uncomplicated malaria
ACTRN12622000638730Phase 3Terminated
- Sponsor
- Ministry of Health
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of artesunate, mefloquine and pyronaridine in Malaria and malaria (2 arms), sponsored by Ministry of Health. Primary endpoint: Therapeutic efficacy by treatment outcome classification. Started Jun 2020; status: terminated.
02
Drugs
artesunatemefloquinepyronaridine
03
Conditions
Malariamalaria
Beyond the preview
Go deeper on ACTRN12622000638730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000638730.